{"id":14460,"date":"2014-11-14T22:44:43","date_gmt":"2014-11-14T20:44:43","guid":{"rendered":"http:\/\/infois.ro\/?p=14460"},"modified":"2014-11-14T22:44:43","modified_gmt":"2014-11-14T20:44:43","slug":"profitul-brut-al-antibiotice-sa-iasi-a-crescut-24","status":"publish","type":"post","link":"http:\/\/infois.ro\/?p=14460","title":{"rendered":"Profitul brut al ANTIBIOTICE SA Ia\u0219i a crescut 24%"},"content":{"rendered":"<p style=\"text-align: justify;\"><a class=\"highslide\" onclick=\"return vz.expand(this)\" href=\"http:\/\/infois.ro\/wp-content\/uploads\/2014\/11\/antibiotice.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft  wp-image-14461\" title=\"antibiotice\" src=\"http:\/\/infois.ro\/wp-content\/uploads\/cache\/2014\/11\/antibiotice\/2155563382.jpg\" alt=\"\" width=\"360\" height=\"538\" \/><\/a><\/p>\n<p style=\"text-align: justify;\"><em>Rezultatele \u00eenregistrate de Antibiotice la finele primelor 9 luni ale anului 2014 arat\u0103 o majorare a profitului \u015fi un ritm de cre\u015ftere al v\u00e2nz\u0103rilor din farmacii (7%) superior ritmului de cre\u015ftere al pie\u0163ei farmaceutice din Rom\u00e2nia (5,2%) (surs\u0103 Cegedim)<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Profit \u00een cre\u015ftere<\/strong><\/p>\n<p style=\"text-align: justify;\">Conform rezultatelor financiare comunicate Bursei de Valori Bucure\u015fti, la finele lunii septembrie a anului 2014, profitul brut a \u00eenregistrat o evolu\u0163ie pozitiv\u0103 ating\u00e2nd valoarea de 23,6 milioane lei, cu 24 procente mai mare \u00een raport cu profitul brut aferent aceleia\u015fi perioade a anului 2013.<\/p>\n<p style=\"text-align: justify;\">Profitul net a avut de asemenea o evolu\u0163ie pozitiv\u0103 \u00een perioada analizat\u0103, \u00eenregistr\u00e2nd valoarea\u00a0 de 20,3 milioane lei, cu 14 procente mai mare dec\u00e2t profitul net \u00eenregistrat \u00een intervalul ianuarie &#8211; septembrie 2013.<\/p>\n<p style=\"text-align: justify;\">Veniturile din v\u00e2nzari din Antibiotice, aferente primelor 9 luni, au atins nivelul de 217,1 milioane lei, situ\u00e2ndu-se la acela\u015fi nivel fa\u0163\u0103 de primele 9 luni ale anului 2013.<\/p>\n<p style=\"text-align: justify;\">V\u00e2nz\u0103rile ob\u0163inute din farmacii (139.7 milioane lei), \u00eenregistreaz\u0103 o cre\u015ftere de 6% fa\u0163\u0103 de 2013, iar pe segmentul Hospital s-a ob\u0163inut o cre\u015ftere de 8%, de la 89,2 milioane lei \u00een 2013 la 96,4 milioane lei \u00een 2014 (sursa Cegedim). Antibiotice \u00ee\u015fi men\u0163ine pozi\u0163ia de lider pe segmentul medicamentelor generice comercializate \u00een spitale.<\/p>\n<p style=\"text-align: justify;\">Pe pia\u0163a medicamentelor generice Antibiotice ocup\u0103 locul 5, cu o cot\u0103 de pia\u0163\u0103 de 6,4%. Totodat\u0103, pe pia\u0163a farmaceutic\u0103 intern\u0103, Antibiotice se situeaz\u0103 pe locul 11, cu o cot\u0103 de pia\u0163\u0103 \u00een cre\u015ftere de la 2,54% (9 luni 2013), la 2.6% (9 luni 2014).<\/p>\n<p style=\"text-align: justify;\"><strong>Produse care aduc valoare<\/strong><\/p>\n<p style=\"text-align: justify;\">Cea mai mare pondere \u00een v\u00e2nz\u0103ri pe pia\u0163a intern\u0103 au de\u0163inut-o, \u00een continuare, \u00een primele nou\u0103 luni, produsele din clasa Antiinfec\u0163ioase de uz sistemic (+9,6 milioane lei), Tract digestiv (+2,8 milioane lei), Preparate Dermatologice (+2,6 milioane lei), Sistem cardiovascular (+1,9 milioane lei), Sistem Musculo-Scheletic (+463 mii lei) \u015fi Antineoplazice (+360 mii lei).<\/p>\n<p style=\"text-align: justify;\">Aceste cre\u015fteri au fost generate at\u00e2t de aportul de produse noi c\u00e2t \u015fi de evolu\u0163ia pozitiv\u0103 a produselor de top ale companiei. Dintre produsele de top se remarc\u0103: Cefort\u00ae inj 1g (aport valoric +7,8 milioane lei), Meropenem ATB inj gama (+4,95 milioane lei), Eficef\u00ae cps gama (+2,1 milioane lei), Glicerina sup gama (+1,2 milioane lei), Ampiplus\u00ae inj (+1,1 milioane lei) \u015fi Nidoflor (+0.98 milioane lei), recunoscute pentru calitatea, eficien\u0163a \u015fi siguran\u0163a lor \u00een r\u00e2ndul speciali\u015ftilor.<\/p>\n<p style=\"text-align: justify;\">Produsele noi ale companiei lansate sau \u00een curs de lansare \u00een 2014 sunt din urmatoarele clase terapeutice:<\/p>\n<p style=\"text-align: justify;\">\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 \u2022 Sistem cardiovascular: Rosuvastatina ATB cpr gama;<\/p>\n<p style=\"text-align: justify;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u2022 Genito-Urinar: Mastoprofen\u00ae ung (progesteron);<\/p>\n<p style=\"text-align: justify;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u2022 Oncologie: Gemcitabina ATB inj gama;<\/p>\n<p style=\"text-align: justify;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u2022 Sistem nervos central: Memantina ATB cpr, Nobixal\u00ae cpr (tianeptina);<\/p>\n<p style=\"text-align: justify;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u2022 Tract digestiv: Silithor\u00ae (supliment hepatoprotector).<\/p>\n<p style=\"text-align: justify;\">\u00cen topul v\u00e2nz\u0103rilor urmeaz\u0103 medicamentele aflate \u00een promovare \u00een anul 2014: Equilibra\u00ae cpr (magneziu+vit B6), Almacor\u00ae cpr gama (amlodipina), Trimetazidina ATB cpr, Alprazolam ATB cpr gama, Ibufen\u00ae cpr (ibuprofen), Bisotens\u00ae cpr gama (bisoprolol), Nolet\u00ae cpr (nebivolol), Spaverin\u00ae cps gama (drotaverina), Roclarin\u00ae cpr (clarithromycina).<\/p>\n<p style=\"text-align: justify;\"><strong>Pia\u0163a extern\u0103<\/strong><\/p>\n<p style=\"text-align: justify;\">Exporturile realizate \u00een primele 9 luni ale anului 2014 au \u00eenregistrat nivelul de 18.358.609 USD comparativ cu anul 2013, c\u00e2nd s-au \u00eenregistrat 18.037.225 USD, trendul v\u00e2nz\u0103rilor la export fiind afectat de conflictele din zona arab\u0103 (Irak \u015fi Libia) \u015fi de situa\u0163ia politic\u0103 din Rusia \u015fi Ucraina.<\/p>\n<p style=\"text-align: justify;\">\u00ab\u00a0Dezvoltarea prezen\u0163ei Antibiotice pe pie\u0163ele interna\u0163ionale reprezint\u0103 un obiectiv strategic al companiei. Proiectele aflate \u00een derulare privind ob\u0163inerea autoriza\u0163iilor de punere pe pia\u0163\u0103, a mai multor produse din portofoliul Antibiotice, parteneriatele complexe care privesc at\u00e2t realizarea dosarelor de produs c\u00e2t \u015fi comercializarea acestora pe diverse pie\u0163e, precum \u015fi consolidarea pozi\u0163iei de lider mondial pentru produc\u0163ia de Nistatin\u0103 (substan\u0163\u0103 activ\u0103)\u00a0vor determina cre\u015fteri privind exporturile \u00een 2015\u00a0\u00bb a declarat Mihai Stoian, Director Dezvoltare Afaceri.<\/p>\n<p style=\"text-align: justify;\">Strategiile companiei \u00een perioada 2013-2014 ce cuprind dezvoltarea activit\u0103\u0163ilor \u015ftiin\u0163ifice \u015fi de cercetare, dezvoltarea parteneriatelor pe principalele pie\u0163e interna\u0163ionale precum \u015fi dezvoltarea portofoliului prin asimilarea de produse noi, vor determina consolidarea afacerii pe termen lung \u015fi cre\u015fterea profitului, at\u00e2t pe pia\u0163a intern\u0103 c\u00e2t \u015fi la nivel interna\u0163ional.<\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Rezultatele \u00eenregistrate de Antibiotice la finele primelor 9 luni ale anului 2014 arat\u0103 o majorare&#8230; <a class=\"meta-more\" href=\"http:\/\/infois.ro\/?p=14460\">more <span class=\"meta-nav\">&raquo;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":14461,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,41],"tags":[74,279,5613,635,3123,1833],"aioseo_notices":[],"_links":{"self":[{"href":"http:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/14460"}],"collection":[{"href":"http:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14460"}],"version-history":[{"count":1,"href":"http:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/14460\/revisions"}],"predecessor-version":[{"id":14462,"href":"http:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/14460\/revisions\/14462"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/media\/14461"}],"wp:attachment":[{"href":"http:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14460"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}